Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Quick question? If I set a sell order for first thing on the 6th, at say 220, would I manage to get out b4 drop?
Ex div tomorrow
TURKU - FINLAND, 28 November 2019 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, today announces that the US Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for Clevegen® (FP-1305), enabling expansion of its ongoing MATINS trial into the US.
The phase I/II MATINS clinical trial, already underway in sites through Europe, is investigating the tolerability, safety and efficacy of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours. Following this US IND acceptance, and as soon as the ongoing dose optimization has been completed, Faron plans to open new study sites in the US to facilitate a rapid expansion of part II of the study, investigating the safety and efficacy of Clevegen in various cancer cohorts. Part I of the trial, to optimize dosing, is ongoing but has already provided data on the different candidate cohorts (e.g. hepatocellular cancer) indicating which should be investigated in part II, alongside colorectal cancer.
Dr Markku Jalkanen, CEO of Faron, said: "We are very pleased to receive this IND approval from the FDA, marking another milestone in the developmet of Clevegen. This approval will allow us to expand MATINS into the US using the same protocol both in Europe and in the US, accelerating our understanding of this novel precision medicine in cancer patients who are refractory to all other treatment options and streamlining the regulatory processes. With the US IND now approved, in due course, we plan to file applications for Breakthrough status in the US and Prime status in Europe, further facilitating regulatory interactions during the development of Clevegen."
Through the MATINS study, Clevegen has demonstrated good tolerability at all dosing levels (0.3-10 mg/kg) without dose limiting toxicity. The previously reported immune activation of MATINS patients (increased circulating CD8+ T cells and CD8+/CD4+ ratio, decreased regulatory T-cells (T-regs) or a substantial increase in mobile natural killer (NK) cells in the blood) will be used to optimize final dosing, as these changes are needed to activate complete adaptive immune response including an activation of B-cells to maintain cancer immunity against that particular cancer type.
I didn’t know they had so many patents
The intellectual property of Faron Pharmaceuticals includes 12 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category. Additionally, Faron Pharmaceuticals has registered 8 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products'.
https://www.ft.com/content/26b58272-a17a-11e9-974c-ad1c6ab5efd1